Last reviewed 2026-05-19 · How we verify

AVX70481 middle dose level

AstriVax Therapeutics · Phase 1 active Biologic ✓ Verified May 2026 Quality 0/100

AVX70481 middle dose level is a Biologic drug developed by AstriVax Therapeutics. It is currently in Phase 1 development.

AVX70481 is a small molecule vaccine candidate, as indicated by its modality on ChEMBL, which is being studied in a trial for the prevention of Yellow Fever and Rabies. The middle dose level of AVX70481 is one of the interventions being evaluated in the trial, along with low and high dose levels of AVX70120.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	AVX70481 middle dose level
Sponsor	AstriVax Therapeutics
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Trial to Evaluate the Safety and Immunogenicity of an Investigational Vaccine for the Prevention of Yellow Fever, and of an Investigational Vaccine for the Prevention of Rabies, in Healthy Adults (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

AVX70481 middle dose level CI brief — competitive landscape report
AVX70481 middle dose level updates RSS · CI watch RSS
AstriVax Therapeutics portfolio CI

Frequently asked questions about AVX70481 middle dose level

What is AVX70481 middle dose level?

AVX70481 middle dose level is a Biologic drug developed by AstriVax Therapeutics.

Who makes AVX70481 middle dose level?

AVX70481 middle dose level is developed by AstriVax Therapeutics (see full AstriVax Therapeutics pipeline at /company/astrivax-therapeutics).

What development phase is AVX70481 middle dose level in?

AVX70481 middle dose level is in Phase 1.

Manufacturer: AstriVax Therapeutics — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing